353 related articles for article (PubMed ID: 9171999)
1. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer.
Jarrard DF; Bova GS; Ewing CM; Pin SS; Nguyen SH; Baylin SB; Cairns P; Sidransky D; Herman JG; Isaacs WB
Genes Chromosomes Cancer; 1997 Jun; 19(2):90-6. PubMed ID: 9171999
[TBL] [Abstract][Full Text] [Related]
2. Frequent alteration of CDKN2 (p16(INK4A)/MTS1) expression in human primary prostate carcinomas.
Chi SG; deVere White RW; Muenzer JT; Gumerlock PH
Clin Cancer Res; 1997 Oct; 3(10):1889-97. PubMed ID: 9815578
[TBL] [Abstract][Full Text] [Related]
3. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.
Herman JG; Merlo A; Mao L; Lapidus RG; Issa JP; Davidson NE; Sidransky D; Baylin SB
Cancer Res; 1995 Oct; 55(20):4525-30. PubMed ID: 7553621
[TBL] [Abstract][Full Text] [Related]
5. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
Gonzalez-Zulueta M; Bender CM; Yang AS; Nguyen T; Beart RW; Van Tornout JM; Jones PA
Cancer Res; 1995 Oct; 55(20):4531-5. PubMed ID: 7553622
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines.
Bender CM; Pao MM; Jones PA
Cancer Res; 1998 Jan; 58(1):95-101. PubMed ID: 9426064
[TBL] [Abstract][Full Text] [Related]
7. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation.
Costello JF; Berger MS; Huang HS; Cavenee WK
Cancer Res; 1996 May; 56(10):2405-10. PubMed ID: 8625319
[TBL] [Abstract][Full Text] [Related]
8. No evidence exists for methylation inactivation of the p16 tumor suppressor gene in ovarian carcinogenesis.
Ryan A; Al-Jehani RM; Mulligan KT; Jacobs IJ
Gynecol Oncol; 1998 Jan; 68(1):14-7. PubMed ID: 9454653
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage.
Nakagawa K; Conrad NK; Williams JP; Johnson BE; Kelley MJ
Oncogene; 1995 Nov; 11(9):1843-51. PubMed ID: 7478613
[TBL] [Abstract][Full Text] [Related]
10. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer.
Ogishima T; Shiina H; Breault JE; Tabatabai L; Bassett WW; Enokida H; Li LC; Kawakami T; Urakami S; Ribeiro-Filho LA; Terashima M; Fujime M; Igawa M; Dahiya R
Clin Cancer Res; 2005 Feb; 11(3):1028-36. PubMed ID: 15709168
[TBL] [Abstract][Full Text] [Related]
11. CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2'deoxycytidine.
Otterson GA; Khleif SN; Chen W; Coxon AB; Kaye FJ
Oncogene; 1995 Sep; 11(6):1211-6. PubMed ID: 7566983
[TBL] [Abstract][Full Text] [Related]
12. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines.
Liu Q; Neuhausen S; McClure M; Frye C; Weaver-Feldhaus J; Gruis NA; Eddington K; Allalunis-Turner MJ; Skolnick MH; Fujimura FK
Oncogene; 1995 Mar; 10(6):1061-7. PubMed ID: 7700630
[TBL] [Abstract][Full Text] [Related]
13. Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma.
Merbs SL; Sidransky D
Invest Ophthalmol Vis Sci; 1999 Mar; 40(3):779-83. PubMed ID: 10067984
[TBL] [Abstract][Full Text] [Related]
14. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA
Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773
[TBL] [Abstract][Full Text] [Related]
15. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells.
Jarrard DF; Kinoshita H; Shi Y; Sandefur C; Hoff D; Meisner LF; Chang C; Herman JG; Isaacs WB; Nassif N
Cancer Res; 1998 Dec; 58(23):5310-4. PubMed ID: 9850055
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of decreased expression of KAI1 metastasis suppressor in human oral carcinogenesis.
Uzawa K; Ono K; Suzuki H; Tanaka C; Yakushiji T; Yamamoto N; Yokoe H; Tanzawa H
Clin Cancer Res; 2002 Mar; 8(3):828-35. PubMed ID: 11895916
[TBL] [Abstract][Full Text] [Related]
17. p21WAF1/CIP1 gene is inactivated in metastatic prostatic cancer cell lines by promoter methylation.
Bott SR; Arya M; Kirby RS; Williamson M
Prostate Cancer Prostatic Dis; 2005; 8(4):321-6. PubMed ID: 16276353
[TBL] [Abstract][Full Text] [Related]
18. Infrequent CDKN2 mutation in human differentiated thyroid cancers.
Tung WS; Shevlin DW; Bartsch D; Norton JA; Wells SA; Goodfellow PJ
Mol Carcinog; 1996 Jan; 15(1):5-10. PubMed ID: 8561866
[TBL] [Abstract][Full Text] [Related]
19. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B.
Herman JG; Jen J; Merlo A; Baylin SB
Cancer Res; 1996 Feb; 56(4):722-7. PubMed ID: 8631003
[TBL] [Abstract][Full Text] [Related]
20. Methylation mediated silencing of TMS1/ASC gene in prostate cancer.
Das PM; Ramachandran K; Vanwert J; Ferdinand L; Gopisetty G; Reis IM; Singal R
Mol Cancer; 2006 Jul; 5():28. PubMed ID: 16848908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
